July 2nd 2025
Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
View More
Expanding Medicaid May Mitigate Disparities in Pancreatic/Gastric Cancers
May 26th 2023Medicaid expansion may help overcome inequities in access to care for pancreatic and gastric cancers, with notable benefit in Black patients, according to an expert from The University of Texas MD Anderson Cancer Center.
NALIRIFOX Demonstrates Consistent Safety in Metastatic Pancreatic Cancer
February 19th 2023Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
Adjuvant Chemo After Neoadjuvant Chemo/Surgery Linked With Survival in PDAC
January 27th 2023Adjuvant chemotherapy following multiagent neoadjuvant chemotherapy and surgical resection produced better overall survival among patients with pancreatic ductal adenocarcinoma vs those who did not receive adjuvant treatment.
Liposomal Irinotecan and NALIRIFOX Delivers Frontline Benefit in Metastatic PDAC
January 21st 2023A combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline yields a statistically significant survival benefit compared with nab-paclitaxel and gemcitabine in a population diagnosed with metastatic pancreatic ductal adenocarcinoma.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer Types
December 15th 2022The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer
October 21st 2022Results from the phase 2 CheckPAC trial indicated that stereotactic body radiotherapy plus nivolumab and ipilimumab produced a promising clinical benefit rate for patients with refractory metastatic pancreatic cancer.
Perioperative/Adjuvant Only Gemcitabine/Nab-Paclitaxel Misses Mark in Resectable PDAC
October 20th 2022Disease-free survival was not reached with perioperative nor adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer, although neoadjuvant chemotherapy yielded a numerical improvement in overall survival, according to data from the phase 2 NEONAX trial.